MESO logo

Mesoblast Limited (MESO) Company Overview

Profile

Full Name:

Mesoblast Limited

Sector:

Healthcare

Industry:

Biotechnology

Country:

Australia

IPO:

January 20, 2010

Indexes:

Not included

Description:

Mesoblast Limited is a biotechnology company focused on developing innovative cell-based therapies. It specializes in using mesenchymal stem cells to treat various conditions, including chronic pain, heart disease, and inflammatory disorders, aiming to improve patient outcomes through advanced regenerative medicine.

Key Details

Price

$19.49

Annual Revenue

$5.90 M(-21.32% YoY)

Annual EPS

-$89.10(+15.38% YoY)

Annual ROE

-17.91%

Beta

1.06

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Aug 28, 2024

Recent annual earnings:

Aug 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 10, 2024

Analyst ratings

Recent major analysts updates

Dec 23, 24 Jefferies
Hold
Dec 19, 24 Piper Sandler
Overweight
Jul 23, 24 Piper Sandler
Overweight
Jun 20, 24 Cantor Fitzgerald
Overweight
Jun 4, 24 Cantor Fitzgerald
Overweight
Sep 21, 23 Cantor Fitzgerald
Overweight
Aug 31, 23 Jefferies
Buy
Aug 31, 23 Cantor Fitzgerald
Overweight
Aug 7, 23 Maxim Group
Hold
Aug 4, 23 William Blair
Market Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Ryoncil® Commercial Launch Update and Product Pipeline
Ryoncil® Commercial Launch Update and Product Pipeline
Ryoncil® Commercial Launch Update and Product Pipeline
MESO
globenewswire.comJanuary 30, 2025

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U.S. commercial launch of Ryoncil® (remestemcel-L) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline.

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
MESO
globenewswire.comJanuary 30, 2025

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second quarter ended December 31, 2024.

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
MESO
zacks.comJanuary 3, 2025

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MESO
zacks.comDecember 19, 2024

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.

US FDA approves Mesoblast's cell therapy for graft-versus-host disease
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
MESO
reuters.comDecember 18, 2024

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.

Mesoblast to be Added to Nasdaq Biotechnology Index
Mesoblast to be Added to Nasdaq Biotechnology Index
Mesoblast to be Added to Nasdaq Biotechnology Index
MESO
globenewswire.comDecember 18, 2024

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast's inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024.

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
MESO
globenewswire.comDecember 2, 2024

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
MESO
globenewswire.comOctober 30, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024.

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
MESO
seekingalpha.comSeptember 30, 2024

Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate that Remestemcel-L significantly improves response rates and survival in pediatric patients. Additionally, Mesoblast's pipeline includes late-stage therapies for chronic low back pain and heart failure, both of which are showing promising results and are nearing regulatory approval.

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
MESO
globenewswire.comSeptember 29, 2024

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approval by the United States Food and Drug Administration (FDA) of Mesoblast's lead product candidate Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast's option and will enable the Company to seamlessly implement its go-to-market commercial strategy. Mesoblast anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Mesoblast Limited?
  • Does Mesoblast Limited pay dividends?
  • What sector is Mesoblast Limited in?
  • What industry is Mesoblast Limited in?
  • What country is Mesoblast Limited based in?
  • When did Mesoblast Limited go public?
  • Is Mesoblast Limited in the S&P 500?
  • Is Mesoblast Limited in the NASDAQ 100?
  • Is Mesoblast Limited in the Dow Jones?
  • When was Mesoblast Limited's last earnings report?
  • When does Mesoblast Limited report earnings?
  • Should I buy Mesoblast Limited stock now?

What is the ticker symbol for Mesoblast Limited?

The ticker symbol for Mesoblast Limited is NASDAQ:MESO

Does Mesoblast Limited pay dividends?

No, Mesoblast Limited does not pay dividends

What sector is Mesoblast Limited in?

Mesoblast Limited is in the Healthcare sector

What industry is Mesoblast Limited in?

Mesoblast Limited is in the Biotechnology industry

What country is Mesoblast Limited based in?

Mesoblast Limited is headquartered in Australia

When did Mesoblast Limited go public?

Mesoblast Limited's initial public offering (IPO) was on January 20, 2010

Is Mesoblast Limited in the S&P 500?

No, Mesoblast Limited is not included in the S&P 500 index

Is Mesoblast Limited in the NASDAQ 100?

No, Mesoblast Limited is not included in the NASDAQ 100 index

Is Mesoblast Limited in the Dow Jones?

No, Mesoblast Limited is not included in the Dow Jones index

When was Mesoblast Limited's last earnings report?

Mesoblast Limited's most recent earnings report was on Aug 28, 2024

When does Mesoblast Limited report earnings?

The next expected earnings date for Mesoblast Limited is Feb 28, 2025

Should I buy Mesoblast Limited stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions